Antibodies for
Immunohistochemistry
Olig2 (211F1.1)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45641 OLIG2 RTU M (211F1.1)
7 ml Ready To Use
45626 OLIG2 0,1 M (211F1.1)
100 µl liquid Concentrated
45627 OLIG2 1 M (211F1.1)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Nuclear
Control
Astrocytoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
2a
/k
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
Product Description
Olig2, a basic helix–loop–helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial
tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak
in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial
tumors, ependymomas, subependymomas, medulloblastomas, and nonneuroepithelial tumors, such as CNS lymphomas, meningiomas,
schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples,
a weak expression is observed in non-tumoral brain tissue (gliosis). In order to characterize cellular subtypes that constitute astrocytomas,
oligoastrocytomas and oligodendrogliomas, double labeling of Olig2 and GFAP has been performed which identified two phenotypically distinct
tumor populations. The first is Olig2+/GFAP– which has an oligodendroglial morphology, corresponding to pure oligodendrogliomas that contain
only oligodendroglial cells; the second is Olig2–/GFAP+ which has an astrocytic phenotype, including not only oligoastrocytomas, but also WHO
astrocytomas. Depending on proportion and spatial clustering of the two phenotypically distinct tumor populations, the tumor (Olig2-/GFAP+) is
classified either as an astrocytoma when both populations are intermingled with a dominance of GFAP+ cells or oligoastrocytoma when there is
some degree of spatial clustering of the GFAP+ cells.
Tumors
Olig2
GFAP
S-100
EMA
Pilocytic Astrocytoma
+/-
+
+
-
Gemistocytic Astrocytoma
+/-
+
+
-
Oligodendrocytoma
+
-
-
-
Ependymoma
-
+/-
+
-
Glioblastoma
+
+/-
+
-
Meningioma
+/-
+/-
-/+
+
Reference
1. Mokhtari K,et al. Neuropathol Appl Neurobiol. 2005; 31:62 – 9.
2. OteroJJ, et al. Journal of Neuro-Oncology. 2011; 104:423-438.
186
